Novartis Diovan "approvable"

Novartis' Diovan (valsartan) supplemental heart failure indication is "approvable" as of Oct. 25 pending further data analysis and, possibly, additional trials. FDA's Cardio-Renal Advisory Committee split on approval of the new indication during the Oct. 11 review (1"The Pink Sheet" Oct. 15, p. 17)